BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20592345)

  • 1. TP53 gene mutations in prostate cancer progression.
    Ecke TH; Schlechte HH; Schiemenz K; Sachs MD; Lenk SV; Rudolph BD; Loening SA
    Anticancer Res; 2010 May; 30(5):1579-86. PubMed ID: 20592345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
    Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
    Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
    Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
    Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE).
    Schlechte HH; Schnorr D; Löning T; Rudolph BD; Pohrt UM; Loening SA
    J Urol; 1997 Mar; 157(3):1049-53. PubMed ID: 9072541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 gene in blood plasma DNA of tumor patients.
    Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
    Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 gene mutations as an independent marker for urinary bladder cancer progression.
    Ecke TH; Sachs MD; Lenk SV; Loening SA; Schlechte HH
    Int J Mol Med; 2008 May; 21(5):655-61. PubMed ID: 18425359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
    Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
    Ecke TH; Lenk SV; Schlechte HH; Loening SA
    Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
    Lerner SE; Blute ML; Bergstralh EJ; Bostwick DG; Eickholt JT; Zincke H
    J Urol; 1996 Jul; 156(1):137-43. PubMed ID: 8648775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
    Vis AN; Schröder FH; van der Kwast TH
    Eur Urol; 2006 Aug; 50(2):258-65. PubMed ID: 16413660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.
    Ecke TH; Schlechte HH; Gunia S; Lenk SV; Loening SA
    Urol Oncol; 2008; 26(5):470-3. PubMed ID: 18367114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels.
    Rogers E; Ohori M; Kassabian VS; Wheeler TM; Scardino PT
    J Urol; 1995 Jan; 153(1):104-10. PubMed ID: 7526002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.